New approaches and prospects for the treatment of myxomatous degeneration of the mitral valve in dogs

Myxomatous mitral valve degeneration (MMVD) is the most common acquired heart disease in small and medium-sized dogs, leading to the development of chronic heart failure. The article summarizes current data (2020–2025) on new directions in the diagnosis, therapy and prevention of MVMD. Particular attention is paid to promising biomarkers (microRNA, SERPINH1, CILP1), innovative drugs (ARNI, SGLT2 inhibitors, antifibrotic agents), as well as approaches to individualizing treatment depending on breed, age and comorbidities. New technologies on cell and gene therapy, nanotechnology and minimally invasive surgical techniques (TEER) are separately highlighted.